When A-list celebrities sign a lucrative contract for a pan masala brand ad, they are ostensibly selling a product, but in reality, they are selling their own credibility. The recent news that the Maharashtra Food and Drug Administration (FDA) has placed Bollywood titans Shah Rukh Khan, Ajay Devgn, and Tiger Shroff under its scanner highlights the growing friction between surrogate advertising tactics and regulatory accountability. This isn’t just a minor regulatory hiccup; it is a direct challenge to the business model that has allowed top-tier actors to rake in millions while endorsing products that are synonymous with health hazards.
For years, the industry has relied on the loophole of surrogate advertising. Instead of promoting the tobacco-laden product directly, brands push ‘elaichi’ or mouth fresheners under the same brand name as their core pan masala business. It is a shell game. Regulators, however, are finally beginning to see through the smoke and mirrors. By targeting the faces of these campaigns, the Maharashtra FDA is shifting the focus from the legal technicalities of the brand names to the moral and public health impact of the celebrity’s influence. It creates a difficult situation for these stars who have built their brands on aspirational value and relatability.
The scale of these deals is staggering. A single pan masala brand ad campaign featuring an actor of SRK’s stature often commands a fee that would make most corporate marketing budgets look like pocket change. Yet, when the fallout begins, the shield of ‘it is just a mouth freshener’ becomes increasingly thin. When thousands of fans view these commercials daily, the line between product category and public endorsement blurs completely. The legal scrutiny now suggests that the government might be gearing up to hold the brand ambassadors as liable as the manufacturers themselves. This would be a massive pivot in how endorsements are structured in India.
Marketing professionals often talk about the ‘multiplier effect’ of celebrity associations. You take a popular face, attach it to a mass-market product, and you watch the retail distribution chain explode with demand. But there is a hidden cost to this strategy that hasn’t been adequately calculated: brand equity depreciation. If a celebrity is constantly associated with a product that faces repeated regulatory investigations, that association eventually sticks to them. The long-term risk for someone like Ajay Devgn, who has essentially become the face of this category, is that their public perception shifts from ‘versatile superstar’ to ‘professional pitchman for controversial goods.’ At some point, the check size no longer compensates for the reputational damage.
Agencies are already starting to walk on eggshells. Creative teams are being asked to find even more abstract ways to promote these brands, moving further away from the product and deeper into lifestyle messaging. But if the FDA’s current stance gains traction across other states, these creative acrobatics might be rendered useless. The regulators are no longer looking for creative cleverness; they are looking for compliance with the spirit of the law, not just the letter of it. If an actor’s face is plastered on a billboard next to a brand that consumers exclusively associate with gutka, no amount of ‘elaichi’ branding will satisfy the authorities.
This situation also signals a potential shift in the influencer-creator economy. The era of ‘no questions asked’ endorsement deals is nearing an end. As public scrutiny intensifies, legal departments in large entertainment houses will likely demand more robust indemnity clauses and stricter vetting processes. No celebrity wants to spend their time answering questions from government health departments about their portfolio choices. We should expect a cooling off period where major stars become much more selective, or at the very least, much more cautious about the secondary brands they align with.
Ultimately, the industry needs to move away from these high-risk, high-reward models. There is a fundamental lack of sustainability in building a campaign strategy around a product category that is perpetually on the verge of being banned or strictly regulated. Marketing is meant to build brands that stand the test of time and public opinion. By leaning into products that rely on regulatory loopholes, brands and their famous faces are essentially borrowing time. Whether it results in fines, public apologies, or a complete exit from the category, the current mess proves that you cannot outrun the reality of the product you choose to promote. Real marketing, zero fluff, means admitting that sometimes, the check just isn’t worth the scrutiny.
